Literature DB >> 26637919

Biochemical Effects of Levothyroxine Withdrawal in Patients with Differentiated Thyroid Cancer.

Georgios Papadakis1, Styliani Kalaitzidou2, Eleni Triantafillou2, Aspasia Drosou2, Kassiani Kakava3, Nikolaos Dogkas4, Theodora Pappa2, Victoria Kaltzidou2, Athanasia Tertipi2, Vassiliki Villiotou4, Anastasios Pappas2.   

Abstract

BACKGROUND: Patients with differentiated thyroid carcinoma (DTC) are submitted to withdrawal of levothyroxine (LT4) aftter thyroidectomy, in order to undergo radiodine ((131)I) treatment. PATIENTS AND METHODS: A total of 345 patients with a history of DTC were enrolled in the study. Their biochemical profile and serum free triiodothyronine (FT3), free thyroxine (FT4) and thyrotropin (TSH) levels were measured during withdrawal of LT4 treatment, and several months after restarting LT4.
RESULTS: During withdrawal, the intra-individual percentage increase in total cholesterol, low density lipoprotein-cholesterol, very low density lipoprotein-cholesterol and triglycerides was of the order of 60-80% and that for high density lipoprotein-cholesterol 30%. Creatinine increased by 30%, whereas Na and K levels decreased by 1%. The increase for creatine phosphate kinase was around 200-300%, for aspartate aminotransferase and alanine aminotransferase 50-80%, for γ-glutamyl transpeptidase 10-20%, and for lactate dehydrogenase 25%. Glucose decreased by 1-4%.
CONCLUSION: Short-term, acute hypothyroidism in patients with DTC induces significant alterations in several biochemical parameters. The presence of other deteriorating diseases should be considered before submitting these patients to LT4 withdrawal. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Differentiated thyroid carcinoma; biochemical alterations; hypothyroidism; thyroxine withdrawal

Mesh:

Substances:

Year:  2015        PMID: 26637919

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Systemic Thyroid Hormone Status During Levothyroxine Therapy In Hypothyroidism: A Systematic Review and Meta-Analysis.

Authors:  Elizabeth A McAninch; Kumar B Rajan; Corinne H Miller; Antonio C Bianco
Journal:  J Clin Endocrinol Metab       Date:  2018-08-15       Impact factor: 5.958

2.  Dyslipidemia Risk in Thyroid Cancer Patients: A Nationwide Population-Based Cohort Study.

Authors:  Youhyun Song; Hye Sun Lee; Goeun Park; Sang-Wook Kang; Ji Won Lee
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-27       Impact factor: 6.055

3.  Stimulated Serum Thyroglobulin Levels versus Unstimulated Serum Thyroglobulin in the Follow-up of Patients with Papillary Thyroid Carcinoma.

Authors:  Saumya Sara Sunny; Julie Hephzibah; David Mathew; Joseph Dian Bondu; Nylla Shanthly; Regi Oommen
Journal:  World J Nucl Med       Date:  2018 Jan-Mar
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.